Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Radiation Use During Vemurafenib and Cobimetinib Treatment in Patients With BRAFV600 Mutated Stage IV or Unresectable Stage III Melanoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01843738
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:33.664338+00:00
Published At
2017-05-24T00:00:00+00:00
Record Updated At
2017-05-24
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["BRAFV600 Mutation", "Stage IV Melanoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2017-05-24"
protocolSection.identificationModule.nctId
"NCT01843738"
protocolSection.identificationModule.officialTitle
"Radiation Use During Vemurafenib and Cobimetinib Treatment in Patients With BRAFV600 Mutated Stage IV or Unresectable Stage III Melanoma"
protocolSection.statusModule.overallStatus
"WITHDRAWN"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • BRAFV600 Mutation (protocolSection.conditionsModule.conditions)
  • Stage IV Melanoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.